Aura Biosciences Files 8-K, Confirms Emerging Growth Status

Ticker: AURA · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, accounting-policy

TL;DR

**Aura Biosciences filed a routine 8-K, confirming its emerging growth company status and opting out of extended accounting transition periods.**

AI Summary

Aura Biosciences, Inc. filed an 8-K on January 8, 2024, indicating an 'Other Events' disclosure. This filing, while not detailing specific financial transactions or major corporate changes, confirms Aura Biosciences' status as an 'emerging growth company' and its election not to use the extended transition period for new accounting standards. For investors, this means the company will adopt new accounting standards at the same time as larger, more established companies, potentially offering more transparent and comparable financial reporting sooner.

Why It Matters

This filing confirms Aura Biosciences' regulatory status and accounting policy choices, which can impact how its financial performance is reported and compared to peers. It signals the company's commitment to adopting new accounting standards without delay.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not disclose any events that would inherently increase or decrease investment risk.

Analyst Insight

This filing is largely administrative. Smart investors should note the company's choice to forgo the extended accounting transition period, which suggests a preference for earlier compliance with new standards, potentially leading to more timely and comparable financial reporting. No immediate action is warranted based solely on this filing.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the primary purpose of this 8-K filing by Aura Biosciences, Inc.?

The primary purpose of this 8-K filing by Aura Biosciences, Inc. is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 8, 2024. It also confirms the company's status as an 'emerging growth company' and indicates its election regarding accounting standards.

What is Aura Biosciences, Inc.'s status regarding 'emerging growth company' as defined by the SEC?

Aura Biosciences, Inc. indicates by check mark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Has Aura Biosciences, Inc. elected to use the extended transition period for new financial accounting standards?

No, Aura Biosciences, Inc. has indicated by check mark that it has elected *not* to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

What is the business address and phone number of Aura Biosciences, Inc. as stated in the filing?

The business address of Aura Biosciences, Inc. is 80 Guest Street, Boston, MA 02135, and its business phone number is (617) 500-8864.

What is the Central Index Key (CIK) for Aura Biosciences, Inc.?

The Central Index Key (CIK) for Aura Biosciences, Inc. is 0001501796.

Filing Stats: 1,057 words · 4 min read · ~4 pages · Grade level 14.7 · Accepted 2024-01-08 07:31:02

Key Financial Figures

Filing Documents

01

Item 8.01. Other Events. Aura Biosciences, Inc. (the "Company") will be conducting meetings with investors attending the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 8, 2024. The Company updated its corporate presentation for use in these meetings. A copy of the corporate presentation is filed as Exhibit 99.1 for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Forward Looking Statements

Forward Looking Statements Statements contained under this Item 8.01 regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; our ability to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates; our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our financial performance; our ability to commercialize our products, if approved; and the implementation of our business model, and strategic plans for our business and product candidates. Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are be

01

Item 9.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate presentation of the Company 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2024 AURA BIOSCIENCES, INC. By: /s/ Julie Feder Julie Feder Chief Financial Officer

View on Read The Filing